VANDA PHARMACEUTICALS INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
VANDA PHARMACEUTICALS INC. (VNDA) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$138.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-12
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$138.91M.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$23.04M, a 472.61% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $6.18M, a 44.86% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was $11.22M, a 73.44% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$138.91M 10-K · filed 2026-02-12 | |
| 2024-12-31 | -$23.04M 10-K · filed 2026-02-12 | |
| 2023-12-31 | $6.18M 10-K · filed 2026-02-12 | |
| 2022-12-31 | $11.22M 10-K · filed 2025-02-14 | |
| 2021-12-31 | $42.22M 10-K · filed 2024-02-08 | |
| 2020-12-31 | $31.67M 10-K · filed 2023-02-09 | |
| 2019-12-31 | $28.79M 10-K · filed 2022-02-24 | |
| 2018-12-31 | $25.12M 10-K · filed 2021-02-11 | $25.10M 10-K · filed 2019-02-19 |
| 2017-12-31 | -$15.69M 10-K · filed 2020-02-26 | -$15.70M 10-K · filed 2018-02-15 |
| 2016-12-31 | -$18.10M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |